Result of AGM

RNS Number : 6573C
Ergomed plc
18 June 2019
 

PRESS RELEASE

FOR IMMEDIATE RELEASE

 

 

Results of 2019 Annual General Meeting

 

Guildford, UK - 18 June 2019: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces the results of voting on the resolutions put to shareholders at its Annual General Meeting held earlier today.  Resolutions 1 to 6 were duly passed, whilst Resolutions 7 and 8 were not passed.

 

Resolutions 1 to 5 were passed on a show of hands.  Details of proxy results were as follows:

 

Resolution number

Votes for

Votes against

Abstentions

1

20,232,290

77,125

8,649

2

20,160,715

156,099

1,250

3

16,997,564

Nil

3,320,500

4

20,316,814

Nil

1,250

5

20,302,774

14,040

1,250

 

Details of voting results for Resolutions 6, 7 and 8 (including proxies) were as follows:

 

Resolution number

Votes for

Votes against

Abstentions

6

27,839,992

10,681,500

1,250

7

27,683,893

10,837,599

1,250

8

27,610,768

10,910,724

1,250

 

The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com

 

ENDS

 

 

 

 

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)






Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Huw Jeremy (Nominated Adviser)


James Black (Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

ergomed@consilium-comms.com

Matthew Neal / Olivia Manser




MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke


 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGLLFEVRTITLIA

Companies

Ergomed (ERGO)
UK 100

Latest directors dealings